Afeyan Noubar Form 4 Moderna / NOUBAR AFEYAN ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

AFEYAN NOUBAR

(Last)

(First)

(Middle)

55 CAMBRIDGE PARKWAY, SUITE 800E

(Street)

CAMBRIDGE

02142

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Moderna, Inc. [ MRNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/22/2021

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/22/2021		S⁽¹⁾		161,887⁽²⁾	D	$159.1794⁽²⁾	19,245,278	I	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.⁽³⁾
Common Stock	02/22/2021		S⁽¹⁾		54,409⁽⁴⁾	D	$160.3709⁽⁴⁾	19,190,869	I	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.⁽³⁾
Common Stock	02/22/2021		S⁽¹⁾		30,808⁽⁵⁾	D	$160.9585⁽⁵⁾	19,160,061	I	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.⁽³⁾
Common Stock	02/22/2021		S⁽¹⁾		250,501⁽⁶⁾	D	$162.3628⁽⁶⁾	18,909,560	I	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.⁽³⁾
Common Stock	02/22/2021		S⁽¹⁾		366,471⁽⁷⁾	D	$163.2527⁽⁷⁾	18,543,089	I	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.⁽³⁾
Common Stock	02/22/2021		S⁽¹⁾		189,200⁽⁸⁾	D	$164.1346⁽⁸⁾	18,353,889	I	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.⁽³⁾
Common Stock	02/22/2021		S⁽¹⁾		165,578⁽⁹⁾	D	$165.4687⁽⁹⁾	18,188,311	I	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.⁽³⁾
Common Stock	02/22/2021		S⁽¹⁾		351,578⁽¹⁰⁾	D	$166.2968⁽¹⁰⁾	17,837,101	I	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.⁽³⁾
Common Stock	02/22/2021		S⁽¹⁾		122,715⁽¹¹⁾	D	$167.1006⁽¹¹⁾	17,714,386	I	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.⁽³⁾
Common Stock	02/22/2021		S⁽¹⁾		58,377⁽¹²⁾	D	$168.1117⁽¹²⁾	17,656,009	I	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.⁽³⁾
Common Stock	02/22/2021		S⁽¹⁾		54,274⁽¹³⁾	D	$169.1401⁽¹³⁾	17,601,735	I	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.⁽³⁾
Common Stock	02/22/2021		S⁽¹⁾		30,968⁽¹⁴⁾	D	$170.0278⁽¹⁴⁾	17,570,797	I	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.⁽³⁾
Common Stock	02/23/2021		S⁽¹⁾		9,985⁽¹⁵⁾	D	$136.482⁽¹⁵⁾	17,560,812	I	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.⁽³⁾
Common Stock	02/23/2021		S⁽¹⁾		122,142⁽¹⁶⁾	D	$137.2906⁽¹⁶⁾	17,438,670	I	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.⁽³⁾
Common Stock	02/23/2021		S⁽¹⁾		46,222⁽¹⁷⁾	D	$138.5585⁽¹⁷⁾	17,392,448	I	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.⁽³⁾
Common Stock	02/23/2021		S⁽¹⁾		56,435⁽¹⁸⁾	D	$139.6447⁽¹⁸⁾	17,336,013	I	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.⁽³⁾
Common Stock	02/23/2021		S⁽¹⁾		102,852⁽¹⁹⁾	D	$140.236⁽¹⁹⁾	17,233,161	I	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.⁽³⁾
Common Stock	02/23/2021		S⁽¹⁾		70,631⁽²⁰⁾	D	$141.4573⁽²⁰⁾	17,162,530	I	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.⁽³⁾
Common Stock	02/23/2021		S⁽¹⁾		117,011⁽²¹⁾	D	$142.7605⁽²¹⁾	17,045,519	I	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.⁽³⁾
Common Stock	02/23/2021		S⁽¹⁾		397,126⁽²²⁾	D	$143.5744⁽²²⁾	16,648,393	I	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.⁽³⁾
Common Stock	02/23/2021		S⁽¹⁾		405,551⁽²³⁾	D	$144.5529⁽²³⁾	16,242,842	I	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.⁽³⁾
Common Stock	02/23/2021		S⁽¹⁾		357,316⁽²⁴⁾	D	$145.4803⁽²⁴⁾	15,885,526	I	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.⁽³⁾
Common Stock	02/23/2021		S⁽¹⁾		307,795⁽²⁵⁾	D	$146.6369⁽²⁵⁾	15,577,731	I	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.⁽³⁾
Common Stock	02/23/2021		S⁽¹⁾		292,483⁽²⁶⁾	D	$147.5729⁽²⁶⁾	15,285,248	I	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.⁽³⁾
Common Stock	02/23/2021		S⁽¹⁾		268,688⁽²⁷⁾	D	$148.521⁽²⁷⁾	15,016,560	I	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.⁽³⁾
Common Stock	02/23/2021		S⁽¹⁾		179,268⁽²⁸⁾	D	$149.626⁽²⁸⁾	14,837,292	I	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.⁽³⁾
Common Stock	02/23/2021		S⁽¹⁾		190,710⁽²⁹⁾	D	$150.5137⁽²⁹⁾	14,646,582	I	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.⁽³⁾
Common Stock	02/23/2021		S⁽¹⁾		23,423⁽³⁰⁾	D	$151.2851⁽³⁰⁾	14,623,159⁽³¹⁾	I	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.⁽³⁾
Common Stock								11,464,359⁽³²⁾	I	By Flagship VentureLabs IV LLC and Flagship Pioneering, Inc.⁽³²⁾
Common Stock								2,101,703	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These sales were effected by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") pursuant to Rule 10b5-1 trading plans adopted on December 23, 2020.

2. Represents 135,986 shares sold by Flagship Fund IV and 25,901 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.65 to $159.61, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

3. Shares held directly by Flagship Fund IV and Flagship Fund IV-Rx. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of each of Flagship Fund IV and Flagship Fund IV-Rx. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

4. Represents 45,703 shares sold by Flagship Fund IV and 8,706 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.65 to $160.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

5. Represents 25,879 shares sold by Flagship Fund IV and 4,929 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.65 to $161.54, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

6. Represents 210,421 shares sold by Flagship Fund IV and 40,080 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $161.79 to $162.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

7. Represents 307,835 shares sold by Flagship Fund IV and 58,636 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $162.79 to $163.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

8. Represents 158,928 shares sold by Flagship Fund IV and 30,272 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.79 to $164.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

9. Represents 139,086 shares sold by Flagship Fund IV and 26,492 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.79 to $165.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

10. Represents 295,016 shares sold by Flagship Fund IV and 56,194 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.79 to $166.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

11. Represents 103,081 shares sold by Flagship Fund IV and 19,634 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.79 to $167.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

12. Represents 49,037 shares sold by Flagship Fund IV and 9,340 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.79 to $168.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

13. Represents 45,589 shares sold by Flagship Fund IV and 8,685 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $168.80 to $169.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

14. Represents 25,989 shares sold by Flagship Fund IV and 4,949 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $169.85 to $170.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

15. Represents 8,387 shares sold by Flagship Fund IV and 1,598 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.01 to $137.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

16. Represents 102,600 shares sold by Flagship Fund IV and 19,542 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.01 to $137.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

17. Represents 38,826 shares sold by Flagship Fund IV and 7,396 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.03 to $139.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

18. Represents 47,406 shares sold by Flagship Fund IV and 9,029 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.05 to $140.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

19. Represents 86,395 shares sold by Flagship Fund IV and 16,457 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140.05 to $140.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

20. Represents 59,330 shares sold by Flagship Fund IV and 11,301 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $141.06 to $142.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

21. Represents 98,290 shares sold by Flagship Fund IV and 18,721 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $142.06 to $143.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

22. Represents 333,586 shares sold by Flagship Fund IV and 63,540 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.06 to $144.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

23. Represents 340,662 shares sold by Flagship Fund IV and 64,889 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.06 to $145.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

24. Represents 300,146 shares sold by Flagship Fund IV and 57,170 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $145.06 to $146.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

25. Represents 258,547 shares sold by Flagship Fund IV and 49,248 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.07 to $147.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

26. Represents 245,686 shares sold by Flagship Fund IV and 46,797 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.07 to $148.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

27. Represents 225,698 shares sold by Flagship Fund IV and 42,990 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.07 to $149.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

28. Represents 150,585 shares sold by Flagship Fund IV and 28,683 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.07 to $150.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

29. Represents 160,196 shares sold by Flagship Fund IV and 30,514 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.08 to $151.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

30. Represents 19,676 shares sold by Flagship Fund IV and 3,747 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.08 to $151.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

31. Following the transactions reported herein, 10,417,023 shares are held directly by Flagship Fund IV and 4,206,136 shares are held directly by Flagship Fund IV-Rx.

32. 11,460,435 shares are held directly by Flagship VentureLabs IV LLC ("VentureLabs IV") and 3,924 shares are held directly by Flagship Pioneering, Inc. ("Flagship Pioneering"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. The reporting person is the sole manager of Flagship Fund IV GP and CEO and sole stockholder of Flagship Pioneering and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Remarks:

	Noubar B. Afeyan, Ph.D. By: /s/ Noubar B. Afeyan, Ph.D.	02/24/2021
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Afeyan Noubar Form 4Moderna / NOUBAR AFEYAN ownership change